News

Oncorena Secures Full Subscription for New Share Issuance

Oncorena Secures Full Subscription for New Share Issuance

Oncorena Announces Successful Subscription of New Shares

Oncorena has reported that it has successfully completed a new share issuance that was fully subscribed, raising a total of 133 million SEK (approximately US$ 13.9 million). These funds are earmarked for the continuation of clinical trials for their innovative treatment targeting renal cancer patients.

Investment for Clinical Study

The financing from this share issuance will enable Oncorena to further its clinical study, known as Oncorella-1, which focuses on the investigational drug ONC175. This study is vital in paving the way for patients suffering from metastatic clear cell or papillary renal cell carcinoma. The initial phase of the study has been completed and the funds will now facilitate the engagement of around 20 additional patients for the next stage, particularly those undergoing hemodialysis. This pivotal part of the study is crucial as it will help determine the effective dosage of ONC175.

Implications of the Research

The advancement of ONC175 is particularly significant because it aims to provide new hope for patients in desperate need of treatment options. With the additional financial resources, Oncorena is positioned to expand its research capabilities, including conducting the clinical study in multiple hospitals.

Leadership Insight

Börje Haraldsson, the CEO and co-founder of Oncorena, expressed gratitude toward the shareholders, especially major investors like HealthCap and Linc, for their unwavering support. He emphasized the importance of these contributions in advancing a therapy that could significantly improve the lives of patients facing serious medical challenges. Haraldsson is optimistic about the potential of ONC175 and anticipates results that could reshape treatment standards in the coming year.

Understanding ONC175

ONC175 is an investigational drug that utilizes synthetically produced orellanine as its active ingredient. This compound targets the kidneys specifically and has shown promise in preclinical studies, demonstrating efficacy in eliminating metastatic renal cancer cells while sparing other organs from adverse effects. The overarching aim is to establish ONC175 as a viable curative option for patients with advanced renal cancer, particularly those who are on dialysis.

Kidney Cancer Statistics

Globally, kidney cancer affects approximately 400,000 individuals each year, as reported by health organizations. Though surgery can effectively treat early-stage cancers, metastatic cases are often more complex and present a significantly poorer prognosis. Current treatments generally involve various targeted therapies that, while helpful, do not guarantee a cure. The need for groundbreaking and effective therapies remains critical.

About Oncorena

Oncorena AB is based in Lund and is committed to innovating treatments for patients battling metastatic renal cancer. Their research, led by Professor Börje Haraldsson at the University of Gothenburg, seeks to bring forth new solutions driven by their findings from in-depth studies. Oncorena continues to receive backing not only from prominent investment entities but also from innovation agencies. They stand committed to their mission of developing treatments that could change the landscape of kidney cancer care.

Frequently Asked Questions

What was the purpose of Oncorena's new share issuance?

The share issuance aimed to raise funds for advancing the Oncorella-1 clinical study of ONC175, which focuses on kidney cancer treatment.

Who are the major investors in Oncorena?

Major investors include HealthCap and Linc, along with several smaller shareholders who supported the new share issuance.

What is ONC175?

ONC175 is an investigational drug designed to treat metastatic renal cell carcinoma using the active component orellanine, which specifically targets the kidneys.

Where is the ongoing clinical study taking place?

The clinical study is being conducted at various hospitals, including a site at Karolinska University Hospital.

Why is there a need for treatments like ONC175?

Current kidney cancer treatments often fall short of being curative, creating an urgent need for innovative therapies that effectively target this aggressive disease.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 258

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 334

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 333

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 282

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 546

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 461

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 466

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 289

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 411

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 335

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading

Top 5 Most Recently Viewed Articles

OneStream Shines as a 5-Time Leader in 2025 Gartner Magic Quadrant

Updated Category News Views 232

OneStream Recognized as a Leader in Financial Planning Software OneStream has achieved significant recognition in the financial planning software landscape by being named a leader in the 2025 Gartner Magic Quadrant. This achievement reflects their exceptional performance in both the Ability to Execute and Completeness of Vision categories. As businesses strive to...

Continue Reading
U.S. Bancorp Welcomes New Head of Consumer Payments Team

Updated Category News Views 307

U.S. Bancorp Appoints New Head of Consumer Payments U.S. Bancorp (BVMF: USBC34) (NYSE: USB) has made a significant move in its leadership with the appointment of Courtney Kelso as the senior executive vice president and head of Payments: Consumer and Small Business (PCS). This announcement underscores U.S. Bancorp's commitment to enhancing its consumer payment solutions...

Continue Reading
The Incredible Growth of Amphenol: A 20-Year Journey

Updated Category News Views 171

Exploring Amphenol's Long-Term Investment Potential Amphenol (NYSE: APH) has shown impressive returns in the stock market over the last two decades. With an average annual return of 22.23%, it has outperformed many market indices by 13.37% on an annualized basis. As of now, Amphenol boasts a market capitalization of approximately $167.52 billion, showcasing its stability...

Continue Reading
ASTM Announces Enhanced Direct Access to Cutting-Edge Platform

Updated Category News Views 361

ASTM's Enhanced Direct Access to Compass Platform Change in reseller relationship invites direct access through ASTM Compass. To better serve its customers' growing demand for advanced digital formats and efficient workflows, ASTM International is shifting its focus to direct sales. This decision comes as they will no longer continue their long-standing reseller...

Continue Reading
Berry Corporation Enhances Financial Framework with Refinancing

Updated Category News Views 108

Berry Corporation's Strategic Refinancing Initiative Berry Corporation (NASDAQ: BRY) has made headlines with the significant completion of a comprehensive refinancing strategy aimed at strengthening its financial foundation. This move, which occurred recently, marks a pivotal moment for the company, enhancing its capital and liquidity and enabling the firm to accelerate...

Continue Reading